#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	3040	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2652	273.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1695	1695	C	397	C,A,G	358,4,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	3040	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2652	273.6	0	HET	.	.	.	C542T,G	.	542	542	C	1053	1053	C	406	C,T,G	280,76,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5110	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4207	291.4	0	.	n	.	0	T695C	SNP	695	695	T	1336	1336	C	388	C	362	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5110	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4207	291.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1978	1978	A	341	A,C	325,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5110	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4207	291.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2612	2612	C	358	C,G	337,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5110	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4207	291.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2686	2686	A	343	A	319	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5110	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4207	291.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	3238	3238	C	300	C,G	281,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	398	folP	855	855	100.0	folP.l6.c4.ctg.1	2357	41.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1590	1592	AGC	51;53;54	A;G,A;C	49;50,1;52	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	906	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	4190	52.4	1	SNP	p	S91F	1	.	.	271	273	TTC	830	832	TTC	68;68;67	T;T;C	60;61;60	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	906	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	4190	52.4	1	SNP	p	D95G	1	.	.	283	285	GGC	842	844	GGC	69;69;69	G;G;C	65;66;64	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	906	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	4190	52.4	1	SNP	p	G95N	0	.	.	283	285	GGC	842	844	GGC	69;69;69	G;G;C	65;66;64	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	344	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1777	47.0	1	SNP	p	G45D	1	.	.	133	135	GAC	721	723	GAC	84;84;84	G;A;C	79;77;81	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	222	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1597	33.5	0	.	n	.	0	A197.	DEL	197	197	A	884	884	A	77	A	71	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	667	750	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3214	55.9	1	SNP	p	D86N	1	D86N	NONSYN	256	258	GAC	566	568	AAC	57;57;59	A;A;C,A,G	39;42;51,2,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	667	750	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3214	55.9	1	SNP	p	S87I	0	.	.	259	261	AGT	569	571	AGT	57;58;60	A;G;T,G	52;50;51,3	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	667	750	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3214	55.9	1	SNP	p	S87R	0	.	.	259	261	AGT	569	571	AGT	57;58;60	A;G;T,G	52;50;51,3	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	667	750	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3214	55.9	1	SNP	p	S87W	0	.	.	259	261	AGT	569	571	AGT	57;58;60	A;G;T,G	52;50;51,3	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	667	750	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3214	55.9	1	SNP	p	S88P	0	.	.	262	264	TCC	572	574	TCC	60;63;62	T,C;C,T;C	51,1;58,2;55	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	667	750	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3214	55.9	0	HET	.	.	.	T281G	.	281	281	T	591	591	T	57	T,G	39,5	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	716	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3244	53.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1874	1876	GGC	67;67;69	G;G;C	62;62;62	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.13.001	penA.13.001	1	1	27	590	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2635	51.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1609	1611	GCA	74;76;77	G;C;A,C	64;63;63,1	penA.13.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	590	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2635	51.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1612	1614	ATC	77;77;76	A;T;C	66;68;67	penA.13.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	590	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2635	51.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1624	1626	GTG	76;76;76	G;T,G;G	66;65,1;67	penA.13.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	590	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2635	51.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1624	1626	GTG	76;76;76	G;T,G;G	66;65,1;67	penA.13.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	590	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2635	51.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2128	2130	ACC	41;41;41	A;C;C	26;33;34	penA.13.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	590	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2635	51.1	1	SNP	p	V502P	0	.	.	1504	1506	GTG	2182	2184	GTG	32;32;33	G,T;T,G;G	25,1;21,1;28	penA.13.001:1:1:V502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	590	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2635	51.1	1	SNP	p	A502V	1	.	.	1504	1506	GTG	2182	2184	GTG	32;32;33	G,T;T,G;G	25,1;21,1;28	penA.13.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	590	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2635	51.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2305	2307	GGC	44;44;44	G;G,T;C,G,T	41;40,1;39,1,1	penA.13.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	590	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2635	51.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2314	2316	GGC	40;41;42	G;G;C	33;34;29	penA.13.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	590	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2635	51.1	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2332	2334	TCG	43;43;43	T,G;C;G,C	32,1;33;36,1	penA.13.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	928	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3559	62.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1791	1793	CCG	92;91;90	C,G,T;C;G,C	68,5,1;80;58,5	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	328	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2337	34.4	0	.	p	.	0	A17T	NONSYN	49	51	GCA	586	588	ACA	35;35;35	A,G;C;A	32,1;33;33	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	328	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2337	34.4	0	.	p	.	0	S22G	NONSYN	64	66	AGC	601	603	GGC	35;35;35	G;G;C,A	33;33;32,1	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	328	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2337	34.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	783	783	C	27	C	25	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	458	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2081	53.5	0	.	p	.	0	E48G	NONSYN	142	144	GAA	570	572	GGA	66;66;66	G;G;A,C	65;63;61,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	458	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2081	53.5	0	.	p	.	0	T87A	NONSYN	259	261	ACT	687	689	GCT	90;90;90	G,A;C;T	81,1;85;81	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	458	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2081	53.5	0	.	p	.	0	T89S	NONSYN	265	267	ACC	693	695	AGC	90;90;91	A;G,C;C,G	80;81,1;81,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	458	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2081	53.5	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	855	857	CAA	87;83;84	C,A;A;A,C	76,2;76;77,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	458	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2081	53.5	0	.	p	.	0	V151A	NONSYN	451	453	GTA	879	881	GCA	83;83;83	G;C,T;A	78;74,1;73	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	458	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2081	53.5	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	987	989	CAA	72;72;72	C,T;A,C;A	68,1;67,1;69	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	458	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2081	53.5	0	.	p	.	0	N189S	NONSYN	565	567	AAC	993	995	AGC	72;72;77	A;G;C	68;68;72	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	458	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2081	53.5	0	.	p	.	0	Y212fs	FSHIFT	634	634	T	1062	1062	T	79	T	76	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	458	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2081	53.5	1	SNP	p	G120K	1	.	.	358	360	AAG	786	788	AAG	79;79;78	A,C;A;G	75,1;76;75	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	458	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2081	53.5	1	SNP	p	A121D	1	.	.	361	363	GAC	789	791	GAC	78;78;78	G;A;C	74;75;75	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	458	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2081	53.5	1	SNP	p	D121N	0	.	.	361	363	GAC	789	791	GAC	78;78;78	G;A;C	74;75;75	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	1276	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5427	56.9	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2237	2239	AAT	63;62;62	A;A;T	61;60;60	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	148	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1380	26.1	1	SNP	p	V57M	1	.	.	169	171	ATG	698	700	ATG	51;50;51	A;T;G	48;47;48	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
